Sector News

Bayer may outsource some drug research – works council

October 17, 2018
Life sciences

Bayer’s chief executive is considering farming out certain drug research activities to cut costs amid slower growth at its pharmaceuticals division, the German company’s works council said on Monday.

The works council cited CEO Werner Baumann as he spoke to staff at a gathering at the group’s Leverkusen headquarters on Sept 28. Reuters reported last month that considerable restructuring efforts at drug research and development, including outsourcing, were underway.

“Werner Baumann spoke about the prospect of weaker growth at the pharmaceutical business and mentioned considerations that some expenditures on pharma research could be outsourced,” the works council said in a statement.

A person familiar with the company told Reuters last month that Bayer, which bought Monsanto for $63 billion this year, is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November.

The savings that Bayer – the inventor of aspirin and maker of Yasmin birth control pills – could make as part of the overhaul would give it financial wiggle room as it competes with larger rivals to buy the right to promising treatments from biotech firms.

Revenues from the drug unit’s top products, blood thinner Xarelto and eye drug Eylea, will peak over the next six years.

A Bayer spokesman said Baumann’s remarks were in reference to plans to intensify external collaborations, which had previously been communicated.

The works council said it wanted more information and demanded wider-ranging job guarantees, beyond a pact that was previously agreed with the company.

By Patricia Weiss

Source: Reuters

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).